Press releases
-
-
-
Internal link ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025
-
-
-
-
-
-
-
-
-
Internal link ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth
-
-
Internal link ProQR Announces First Patient Dosed in Phase 1/2 Aurora Trial of QR-1123 for Autosomal Dominant Retinitis Pigmentosa
-
Internal link ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa
-
Internal link ProQR to Present at Upcoming Scientific Conferences
-
Internal link ProQR to Present at Upcoming Investor Conferences
-
-
-
-
-
Internal link ProQR Receives Rare Pediatric Disease Designation from FDA for Sepofarsen for the Treatment of LCA10
-
Internal link ProQR annonce des premiers résultats positifs pour l'essai de phase 1/2 du sepofarsen chez des patients souffrant d'ACL10
-
Internal link ProQR Announces Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients
-
Internal link ProQR to Present Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients ahead of AAO